Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity - PubMed (original) (raw)

Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity

Ozer Arican et al. Mediators Inflamm. 2005.

Abstract

Recent progress in the understanding of psoriasis has shown that the regulation of local and systemic cytokines plays an important role in its pathogenesis. The most often used psoriasis score is the psoriasis area and severity index (PASI). A simple laboratory test from a blood sample would be an attractive, patient-independent, and observer-independent marker of disease severity. To this end, we evaluated the association of serum levels of some proinflammatory cytokines in vivo and their correlation with severity of psoriasis. The serum levels of cytokines levels were determined with the use of the ELISA method. All mean values except IL-17 levels of patients were significantly higher than those of controls. There was a significant correlation between serum levels of IFN-gamma, IL-12, IL-17, and IL-18, and severity of the disease. Psoriasis can be described as a T-cell-mediated disease, with a complex role for a variety of cytokines, which has led to the development of new immunomodulatory therapies. In this study, serum TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, and IL-18 levels were significantly higher in active psoriatic patients than in controls. Furthermore, high levels of IFN-gamma, IL-12, and IL-18 correlated with the clinical severity and activity of psoriasis, and those measurements of serum levels of these cytokines may be objective parameters for the disease severity.

PubMed Disclaimer

Figures

Figure 1

Figure 1

(a) IFN-γ, (b) TNF-α, (c) IL-6, (d) IL-8, (e) IL-12, and (f) IL-18 serum levels of psoriatic patients and controls in box plot graphics (○: outliers).

Figure 1

Figure 1

(a) IFN-γ, (b) TNF-α, (c) IL-6, (d) IL-8, (e) IL-12, and (f) IL-18 serum levels of psoriatic patients and controls in box plot graphics (○: outliers).

Figure 1

Figure 1

(a) IFN-γ, (b) TNF-α, (c) IL-6, (d) IL-8, (e) IL-12, and (f) IL-18 serum levels of psoriatic patients and controls in box plot graphics (○: outliers).

Figure 1

Figure 1

(a) IFN-γ, (b) TNF-α, (c) IL-6, (d) IL-8, (e) IL-12, and (f) IL-18 serum levels of psoriatic patients and controls in box plot graphics (○: outliers).

Figure 1

Figure 1

(a) IFN-γ, (b) TNF-α, (c) IL-6, (d) IL-8, (e) IL-12, and (f) IL-18 serum levels of psoriatic patients and controls in box plot graphics (○: outliers).

Figure 1

Figure 1

(a) IFN-γ, (b) TNF-α, (c) IL-6, (d) IL-8, (e) IL-12, and (f) IL-18 serum levels of psoriatic patients and controls in box plot graphics (○: outliers).

Similar articles

Cited by

References

    1. Lowes MA, Lew W, Krueger JG. Current concepts in the immunopathogenesis of psoriasis. Dermatol Clin. 2004;22(4):349–369. - PubMed
    1. Bos JD, De Rie MA. The pathogenesis of psoriasis: immunological facts and speculations. Immunol Today. 1999;20(1):40–46. - PubMed
    1. Griffiths CEM. The immunological basis of psoriasis. J Eur Acad Dermatol Venereol. 2003;17(suppl 2):1–5. - PubMed
    1. Chamian F, Krueger JG. Psoriasis vulgaris: an interplay of T lymphocytes, dendritic cells, and inflammatory cytokines in pathogenesis. Curr Opin Rheumatol. 2004;16(4):331–337. - PubMed
    1. Gudjonsson JE, Johnston A, Sigmundsdottir H, Valdimarsson H. Immunopathogenic mechanisms in psoriasis. Clin Exp Immunol. 2004;135(1):1–8. - PMC - PubMed

MeSH terms

Substances

LinkOut - more resources